Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
Status:
Terminated
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
Part A (Phase IIa):
Primary objectives:
The study part A is designed to investigate whether the use of regorafenib eye drops can help
patients with neovascular (wet) Age-Related Macular Degeneration (wAMD) to see better after 4
weeks and 12 weeks after inclusion into this study.
Secondary objectives:
The study will also evaluate the safety and tolerability of the regorafenib eye drops.
Part B (Phase IIb):
Primary objectives:
The study part B is designed to investigate:
- how often the regorafenib eye drops need to be given per day
- whether the use of regorafenib eye drops can help patients with neovascular (wet)
Age-Related Macular Degeneration (wAMD) to see better after 4 weeks and 12 weeks after
inclusion into this study.
Secondary objectives:
The study will also evaluate how the different dosings of regorafenib eye drops affect
patients vision, the safety and the tolerability.